ZBP1 not RIPK1 mediates tumor necroptosis in breast cancer.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
11 05 2021
Historique:
received: 03 04 2020
accepted: 12 04 2021
entrez: 12 5 2021
pubmed: 13 5 2021
medline: 2 6 2021
Statut: epublish

Résumé

Tumor necrosis happens commonly in advanced solid tumors. We reported that necroptosis plays a major role in tumor necrosis. Although several key necroptosis regulators including receptor interacting protein kinase 1 (RIPK1) have been identified, the regulation of tumor necroptosis during tumor development remains elusive. Here, we report that Z-DNA-binding protein 1 (ZBP1), not RIPK1, mediates tumor necroptosis during tumor development in preclinical cancer models. We found that ZBP1 expression is dramatically elevated in necrotic tumors. Importantly, ZBP1, not RIPK1, deletion blocks tumor necroptosis during tumor development and inhibits metastasis. We showed that glucose deprivation triggers ZBP1-depedent necroptosis in tumor cells. Glucose deprivation causes mitochondrial DNA (mtDNA) release to the cytoplasm and the binding of mtDNA to ZBP1 to activate MLKL in a BCL-2 family protein, NOXA-dependent manner. Therefore, our study reveals ZBP1 as the key regulator of tumor necroptosis and provides a potential drug target for controlling tumor metastasis.

Identifiants

pubmed: 33976222
doi: 10.1038/s41467-021-23004-3
pii: 10.1038/s41467-021-23004-3
pmc: PMC8113527
doi:

Substances chimiques

RNA-Binding Proteins 0
ZBP1 protein, human 0
Zbp1 protein, mouse 0
RIPK1 protein, human EC 2.7.11.1
Receptor-Interacting Protein Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

2666

Références

Galluzzi, L. et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 25, 486–541 (2018).
pubmed: 29362479 pmcid: 5864239 doi: 10.1038/s41418-017-0012-4
Green, D. R. The coming decade of cell death research: five riddles. Cell 177, 1094–1107 (2019).
pubmed: 31100266 pmcid: 6534278 doi: 10.1016/j.cell.2019.04.024
Galluzzi, L. & Kroemer, G. Necroptosis: a specialized pathway of programmed necrosis. Cell 135, 1161–1163 (2008).
pubmed: 19109884 doi: 10.1016/j.cell.2008.12.004
Christofferson, D. E. & Yuan, J. Necroptosis as an alternative form of programmed cell death. Curr. Opin. Cell Biol. 22, 263–268 (2010).
pubmed: 20045303 pmcid: 2854308 doi: 10.1016/j.ceb.2009.12.003
Wallach, D., Kang, T. B., Dillon, C. P. & Green, D. R. Programmed necrosis in inflammation: toward identification of the effector molecules. Science 352, aaf2154 (2016).
pubmed: 27034377 doi: 10.1126/science.aaf2154
Cai, Z. et al. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nat. Cell Biol. 16, 55–65 (2014).
pubmed: 24316671 doi: 10.1038/ncb2883
Chen, X. et al. Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death. Cell Res. 24, 105–121 (2014).
pubmed: 24366341 doi: 10.1038/cr.2013.171
Dondelinger, Y. et al. MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep. 7, 971–981 (2014).
pubmed: 24813885 doi: 10.1016/j.celrep.2014.04.026
Wang, H. et al. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol. Cell 54, 133–146 (2014).
pubmed: 24703947 doi: 10.1016/j.molcel.2014.03.003
Kaiser, W. J. et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J. Biol. Chem. 288, 31268–31279 (2013).
pubmed: 24019532 pmcid: 3829437 doi: 10.1074/jbc.M113.462341
Upton, J. W., Kaiser, W. J. & Mocarski, E. S. DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. Cell Host Microbe 11, 290–297 (2012).
pubmed: 22423968 pmcid: 3531981 doi: 10.1016/j.chom.2012.01.016
Caruso, R. et al. Histologic coagulative tumour necrosis as a prognostic indicator of aggressiveness in renal, lung, thyroid and colorectal carcinomas: a brief review. Oncol. Lett. 3, 16–18 (2012).
pubmed: 22740848 doi: 10.3892/ol.2011.420
Brown, J. M. & William, W. R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 4, 437–447 (2004).
pubmed: 15170446 doi: 10.1038/nrc1367
Gatenby, R. A. & Gillies, R. J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4, 891–899 (2004).
doi: 10.1038/nrc1478 pubmed: 15516961
Makki, J. Diversity of breast carcinoma: histological subtypes and clinical relevance. Clin. Med Insights Pathol. 8, 23–31 (2015).
pubmed: 26740749 pmcid: 4689326 doi: 10.4137/CPath.S31563
Richards, C. H., Mohammed, Z., Qayyum, T., Horgan, P. G. & McMillan, D. C. The prognostic value of histological tumor necrosis in solid organ malignant disease: a systematic review. Future Oncol. 7, 1223–1235 (2011).
pubmed: 21992733 doi: 10.2217/fon.11.99
Jiao, D. et al. Necroptosis of tumor cells leads to tumor necrosis and promotes tumor metastasis. Cell Res. 28, 868–870 (2018).
pubmed: 29941926 pmcid: 6082890 doi: 10.1038/s41422-018-0058-y
Seifert, L. et al. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. Nature 532, 245–249 (2016).
pubmed: 27049944 pmcid: 4833566 doi: 10.1038/nature17403
Yatim, N. et al. RIPK1 and NF-kappaB signaling in dying cells determines cross-priming of CD8(+) T cells. Science 350, 328–334 (2015).
pubmed: 26405229 pmcid: 4651449 doi: 10.1126/science.aad0395
Patel, S. et al. RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases. Cell Death Differ. 27, 161–175 (2020).
pubmed: 31101885 doi: 10.1038/s41418-019-0347-0
Trikha, P. et al. E2f3 in tumor macrophages promotes lung metastasis. Oncogene 35, 3636–3646 (2016).
pubmed: 26549026 doi: 10.1038/onc.2015.429
Pei, X. F. et al. Explant-cell culture of primary mammary tumors from MMTV-c-Myc transgenic mice. Vitr. Cell Dev. Biol. Anim. 40, 14–21 (2004).
doi: 10.1290/1543-706X(2004)40<14:ECOPMT>2.0.CO;2
Ito, Y. et al. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science 353, 603–608 (2016).
pubmed: 27493188 pmcid: 5444917 doi: 10.1126/science.aaf6803
Xu, Q. et al. The cytoplasmic nuclear receptor RARgamma controls RIP1 initiated cell death when cIAP activity is inhibited. Nat. Commun. 8, 425 (2017).
pubmed: 28871172 pmcid: 5583178 doi: 10.1038/s41467-017-00496-6
Lin, E. Y. et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am. J. Pathol. 163, 2113–2126 (2003).
pubmed: 14578209 pmcid: 1892434 doi: 10.1016/S0002-9440(10)63568-7
Fu, Y. et al. Cloning of DLM-1, a novel gene that is up-regulated in activated macrophages, using RNA differential display. Gene 240, 157–163 (1999).
pubmed: 10564822 doi: 10.1016/S0378-1119(99)00419-9
Koo, G.-B. et al. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res. 25, 707–725 (2015).
pubmed: 25952668 pmcid: 4456623 doi: 10.1038/cr.2015.56
Chew, W. L. et al. A multifunctional AAV-CRISPR-Cas9 and its host response. Nat. Methods 13, 868–874 (2016).
pubmed: 27595405 pmcid: 5374744 doi: 10.1038/nmeth.3993
Ashkenazi, A. & Dixit, V. M. Death receptors: signaling and modulation. Science 281, 1305–1308 (1998).
pubmed: 9721089 doi: 10.1126/science.281.5381.1305
Guicciardi, M. E. & Gores, G. J. Life and death by death receptors. FASEB J. 23, 1625–1637 (2009).
pubmed: 19141537 pmcid: 2698650 doi: 10.1096/fj.08-111005
Ingram, J. P. et al. ZBP1/DAI drives RIPK3-mediated cell death induced by IFNs in the absence of RIPK1. J. Immunol. 203, 1348–1355 (2019).
pubmed: 31358656 doi: 10.4049/jimmunol.1900216
Cheong, J. H. et al. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol. Cancer Ther. 10, 2350–2362 (2011).
pubmed: 21992792 pmcid: 3237863 doi: 10.1158/1535-7163.MCT-11-0497
Li, X. X. et al. Nuclear receptor Nur77 facilitates melanoma cell survival under metabolic stress by protecting fatty acid oxidation. Mol. Cell 69, 480–492 e487 (2018).
pubmed: 29395065 doi: 10.1016/j.molcel.2018.01.001
Sridharan, H. et al. Murine cytomegalovirus IE3‐dependent transcription is required for DAI/ZBP1‐mediated necroptosis. EMBO Rep. 18, 1429–1441 (2017).
pubmed: 28607035 pmcid: 5538628 doi: 10.15252/embr.201743947
Chen, D. et al. PUMA amplifies necroptosis signaling by activating cytosolic DNA sensors. Proc. Natl Acad. Sci. USA 115, 3930–3935 (2018).
pubmed: 29581256 doi: 10.1073/pnas.1717190115 pmcid: 5899441
Sorvina, A. et al. Mitochondrial imaging in live or fixed tissues using a luminescent iridium complex. Sci. Rep. 8, 8191 (2018).
pubmed: 29844412 pmcid: 5974328 doi: 10.1038/s41598-018-24672-w
Chen, J. et al. An in situ atlas of mitochondrial DNA in mammalian tissues reveals high content in stem and proliferative compartments. Am. J. Pathol. 190, 1565–1579 (2020).
pubmed: 32304697 doi: 10.1016/j.ajpath.2020.03.018 pmcid: 7338910
Schock, S. N. et al. Induction of necroptotic cell death by viral activation of the RIG-I or STING pathway. Cell Death Differ. 24, 615–625 (2017).
pubmed: 28060376 pmcid: 5384020 doi: 10.1038/cdd.2016.153
Seo, Y. W. et al. The molecular mechanism of Noxa-induced mitochondrial dysfunction in p53-mediated cell death. J. Biol. Chem. 278, 48292–48299 (2003).
pubmed: 14500711 doi: 10.1074/jbc.M308785200
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
pubmed: 21376230 doi: 10.1016/j.cell.2011.02.013
Najafov, A., Chen, H. & Yuan, J. Necroptosis and cancer. Trends Cancer 3, 294–301 (2017).
pubmed: 28451648 pmcid: 5402749 doi: 10.1016/j.trecan.2017.03.002
Liu, Z. G. & Jiao, D. Necroptosis, tumor necrosis and tumorigenesis. Cell Stress 4, 1–8 (2019).
pubmed: 31922095 pmcid: 6946014 doi: 10.15698/cst2020.01.208
Newton, K. et al. RIPK1 inhibits ZBP1-driven necroptosis during development. Nature 540, 129–133 (2016).
pubmed: 27819682 doi: 10.1038/nature20559
Rothenburg, S., Schwartz, T., Koch-Nolte, F. & Haag, F. Complex regulation of the human gene for the Z-DNA binding protein DLM-1. Nucleic Acids Res. 30, 993–1000 (2002).
pubmed: 11842111 pmcid: 100341 doi: 10.1093/nar/30.4.993
Kuriakose, T. & Kanneganti, T. D. ZBP1: innate sensor regulating cell death and inflammation. Trends Immunol. 39, 123–134 (2018).
pubmed: 29236673 doi: 10.1016/j.it.2017.11.002
Yang, D. et al. ZBP1 mediates interferon-induced necroptosis. Cell Mol Immunol. 17, 356–368 (2020).
Frank, T. et al. Cell cycle arrest in mitosis promotes interferon-induced necroptosis. Cell Death Differ. 26, 2046–2060 (2019).
pubmed: 30742091 pmcid: 6748087 doi: 10.1038/s41418-019-0298-5
Thyrell, L. et al. Interferon alpha-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway. J. Biol. Chem. 279, 24152–24162 (2004).
pubmed: 15056668 doi: 10.1074/jbc.M312219200
Jeong, S. et al. Cannabidiol-induced apoptosis is mediated by activation of Noxa in human colorectal cancer cells. Cancer Lett. 447, 12–23 (2019).
pubmed: 30660647 doi: 10.1016/j.canlet.2019.01.011
Liang, L. et al. Role of Noxa in proliferation, apoptosis, and autophagy in human adenoid cystic carcinoma. J. Oral. Pathol. Med. 48, 52–59 (2019).
pubmed: 30290043 doi: 10.1111/jop.12787
Colaprico, A. et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 44, e71 (2016).
pubmed: 26704973 doi: 10.1093/nar/gkv1507
Gao, G. F. et al. Before and after: comparison of legacy and harmonized TCGA genomic data commons’ data. Cell Syst. 9, 24–34 e10 (2019).
pubmed: 31344359 pmcid: 6707074 doi: 10.1016/j.cels.2019.06.006
R: a language and environment for statistical computing (R Foundation for Statistical Computing, Vienna, Austria, 2018).
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
pubmed: 25605792 pmcid: 4402510 doi: 10.1093/nar/gkv007
Britt-Marie Ljung, B. M. et al. Cell dissociation techniques in human breast cancer Variations in tumor cell viability and DNA ploidy. Breast Cancer Res. Treat. 13, 153–159 (1989).
doi: 10.1007/BF01806527
Sharon, Y., Alon, L., Glanz, S., Servais, C. & Erez, N. Isolation of normal and cancer-associated fibroblasts from fresh tissues by Fluorescence Activated Cell Sorting (FACS). J. Vis. Exp. 17, e4425, (2013).
Fischer, A. H., Jacobson, K. A., Rose, J. & Zeller, R. Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc. 2008, pdb.prot4986, (2008).
Elmore, S. A. et al. Recommendations from the INHAND Apoptosis/Necrosis Working Group. Toxicol. Pathol. 44, 173–188 (2016).
pubmed: 26879688 pmcid: 4785073 doi: 10.1177/0192623315625859

Auteurs

Jin Young Baik (JY)

National Cancer Institute; National Institutes of Health, Laboratory of Immune Cell Biology, Bethesda, MD, USA.

Zhaoshan Liu (Z)

National Cancer Institute; National Institutes of Health, Laboratory of Immune Cell Biology, Bethesda, MD, USA.

Delong Jiao (D)

National Cancer Institute; National Institutes of Health, Laboratory of Immune Cell Biology, Bethesda, MD, USA.

Hyung-Joon Kwon (HJ)

National Cancer Institute; National Institutes of Health, Laboratory of Immune Cell Biology, Bethesda, MD, USA.

Jiong Yan (J)

National Cancer Institute; National Institutes of Health, Laboratory of Immune Cell Biology, Bethesda, MD, USA.

Chamila Kadigamuwa (C)

National Cancer Institute; National Institutes of Health, Laboratory of Immune Cell Biology, Bethesda, MD, USA.

Moran Choe (M)

National Cancer Institute; National Institutes of Health, Laboratory of Immune Cell Biology, Bethesda, MD, USA.

Ross Lake (R)

National Cancer Institute; National Institutes of Health, Laboratory of Genitourinary Cancer Pathogenesis, Bethesda, MD, USA.

Michael Kruhlak (M)

National Cancer Institute; National Institutes of Health, Laboratory of Cancer Biology and Genetics, Bethesda, MD, USA.

Mayank Tandon (M)

National Cancer Institute; National Institutes of Health, Collaborative Bioinformatics Resource, Bethesda, MD, USA.
Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.

Zhenyu Cai (Z)

Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.

Swati Choksi (S)

National Cancer Institute; National Institutes of Health, Laboratory of Immune Cell Biology, Bethesda, MD, USA.

Zheng-Gang Liu (ZG)

National Cancer Institute; National Institutes of Health, Laboratory of Immune Cell Biology, Bethesda, MD, USA. zgliu@helix.nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH